about
Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjectsTargeting Cell Survival Proteins for Cancer Cell DeathGanetespib: research and clinical developmentTargeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial ResistanceRecent advances in malaria drug discoveryHeat shock transcription factor 1 as a therapeutic target in neurodegenerative diseasesSynthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90Synthesis of benzoquinone ansamycin-inspired macrocyclic lactams from shikimic acidSynthesis of macrolactam analogues of radicicol and their binding to heat shock protein Hsp90Elucidation of the Hsp90 C-terminal inhibitor binding siteHerbimycins D-F, ansamycin analogues from Streptomyces sp. RM-7-15High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888Prediction of promiscuous p-glycoprotein inhibition using a novel machine learning schemeHSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosisSynthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.Probing the probes: fitness factors for small molecule tools.Protein chaperones: a composition of matter review (2008 - 2013).The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90Contribution of viral mimics of cellular genes to KSHV infection and disease.The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition.3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues.Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.Construction of a crown ether-like supramolecular library by conjugation of genetically-encoded peptide linkers displayed on bacteriophage T7.Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomasMolecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.Ion-permeable membrane for on-chip preconcentration and separation of cancer marker proteinsHsp90 molecular chaperone inhibitors: are we there yet?Broad substrate specificity of the amide synthase in S. hygroscopicus--new 20-membered macrolactones derived from geldanamycin.The Chemical Biology of Molecular Chaperones--Implications for Modulation of ProteostasisDevelopment of Noviomimetics as C-Terminal Hsp90 InhibitorsRadiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.Recent updates on the development of ganetespib as a Hsp90 inhibitor.
P2860
Q24600166-49DC5EC7-0F29-45A3-A447-EDED556D45F9Q26765447-23274DA7-89AE-4F39-B354-225E07DFA069Q26798645-F4882709-1185-4938-9FAB-92BC2D5A2C33Q26864290-921290E5-B6E9-48E2-96BA-8A4235A8678DQ27010534-050FD5DE-5B95-4743-AB54-570661FE6287Q27026884-7C642B9F-1F1F-4771-AF7B-8F6E96F6C352Q27676888-8AD1D3B0-E796-443B-ABDA-348529508F67Q27684361-45969205-0FFC-4B14-BCCA-16E322E6FA2FQ27688922-E9BEF668-8AB9-4828-9013-0596A1EBC771Q28236934-DEC316D2-C305-4DEA-9873-E8239F5B4C8CQ28296599-2933B94C-5DA5-4BC4-94F6-CBA3FD4699DBQ28477348-B69DD1D3-5419-4917-80B6-A4C7C68CC6ACQ28481547-8829CA20-1932-4661-B396-2F9E01651CC2Q28569716-F5017F4C-F2E3-4143-83BA-90EA8C5E409BQ33555574-738E80D4-B7F9-454B-ABD8-4D9F71BC121CQ33943421-15D27DE3-FEFD-49ED-932A-F714D9E8ABD3Q34001269-2AFF32EE-0345-43D7-9C20-B9B4705FE9DFQ34013266-63F2ABE9-4F89-47AA-909D-10E4AD8A88CCQ34089152-34F98EC1-20B3-42A8-8C13-6BB163B56C98Q34288879-A38BFF95-A92A-4FCF-9094-B3AF6972F636Q34303583-7E82ECC0-031D-4DF2-B2D6-987DC3CC01A3Q34407501-7D9CB10F-096D-444C-A98F-788F3FC0CA6BQ34547161-ABCA2031-2E09-43D7-84A2-33EA070E6C5EQ34680439-B4DB5003-3FBE-4331-A713-CE49031C5CFFQ34915636-D4C05280-279C-40B9-9121-5E6C2911A84AQ35118082-8EEBDD76-A985-4924-83B9-F3640C2EE2E3Q35192933-3EF21113-6B29-466C-B89F-1E5E7895F744Q35196261-066E7027-A447-439A-A438-A1D930229898Q35313148-E6F8BE6F-B3E2-4978-9FDF-9C3D6C71079DQ35429717-FDC7DD84-3D49-40E0-8ED4-595A437FB28DQ35622975-1D6B2C6B-1DF1-4C0B-A940-DE68F45BB0E8Q35655105-D0FEB79E-9450-4801-9C32-19A64A416B81Q35797661-03B055E0-27CE-483E-943E-3BE21A4A29D8Q36059002-FD77D159-F9B3-47D4-AC11-EF45CBA129FDQ36473154-DB48AC3E-BCEC-4DD1-9354-549B5D715604Q36654876-9D0B7B16-58C4-4A23-86B5-DBFEDAFD5174Q36844176-443C0F54-B836-4E35-A76B-1AEE3779B9CFQ37827173-D2A4AB48-8199-42F6-B7EA-F4677F261584Q37891987-37EBD9E1-68A6-405F-B935-94459F887FACQ38065103-20F7B376-57BB-4C89-9D2B-1FAA3D98AC2D
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Heat shock protein 90: inhibitors in clinical trials.
@ast
Heat shock protein 90: inhibitors in clinical trials.
@en
Heat shock protein 90: inhibitors in clinical trials.
@nl
type
label
Heat shock protein 90: inhibitors in clinical trials.
@ast
Heat shock protein 90: inhibitors in clinical trials.
@en
Heat shock protein 90: inhibitors in clinical trials.
@nl
prefLabel
Heat shock protein 90: inhibitors in clinical trials.
@ast
Heat shock protein 90: inhibitors in clinical trials.
@en
Heat shock protein 90: inhibitors in clinical trials.
@nl
P2093
P356
P1476
Heat shock protein 90: inhibitors in clinical trials
@en
P2093
Daniel Perret
Joseph W Arndt
Marco A Biamonte
Ryan Van de Water
Wen-Cherng Lee
P356
10.1021/JM9004708
P407
P577
2010-01-01T00:00:00Z